The Efficacy of Yunnan Baiyao on Haemostasis and Antiulcer: a Systematic Review and Meta-analysis of Randomized Controlled Trials
Overview
Affiliations
Yunnan Baiyao (YNBY) is widely used to treat rhexis haemorrhage and ulcer in China. This meta-analysis was conducted to determine the efficacy of YNBY on local haemostasis and antiulcer. Randomized controlled trials were included on condition that assessing the effects of YNBY with/without routine drugs versus the same routine drugs on haemorrhage or ulcer after searching major databases. Data were validated, extracted and synthesized using relative risk (RR) for dichotomous data using random effects models. Fifty-five studies involving 5,150 patients were identified. (1) YNBY alone for haemorrhage (RR = 1.16; 95% CI 1.06 to 1.28) (2) YNBY alone for antiulcer (RR = 1.26; 95% CI 1.03 to 1.53). We found certain effects on ulcerative colitis (RR = 1.22) and skin ulcer (RR = 1.20) in subgroup analysis. (3) YNBY plus routine haemostatic drugs for haemorrhage (RR = 1.23; 95% CI 1.17 to 1.29) with a significant funnel plot asymmetry (Begg's test, p = 0). (4) YNBY plus routine antiulcer drugs for antiulcer (RR = 1.18; 95% CI 1.05 to 1.33). Treatment effect in the 2(nd) and 4(th) group was unstable when RCTs at high risk of bias were excluded. Great heterogeneities and possible publication bias were found among the trials which preclude certain conclusions. The existing data showed that YNBY alone was helpful in treating uterine haemorrhage, ulcerative colitis and skin ulcer. YNBY plus routine antiulcer drugs was more effective in treating ulcerative colitis versus antiulcer drugs alone.
Effects of Yunnan Baiyao on the Differentiation of HPDLFs on the Bio-Oss Collagen Scaffold in vivo.
Yu X, Wang J, Han Q, Chu W, Lu S, Liu Y Int J Gen Med. 2022; 15:5395-5405.
PMID: 35685694 PMC: 9173728. DOI: 10.2147/IJGM.S359921.
Zhang Q, Zhang A, Wu F, Wang X Molecules. 2022; 27(10).
PMID: 35630682 PMC: 9143197. DOI: 10.3390/molecules27103208.
Ren X, Zhang M, Zhang W, Xie J, Luo H, Zhang H Evid Based Complement Alternat Med. 2022; 2022:3764444.
PMID: 35178101 PMC: 8843773. DOI: 10.1155/2022/3764444.
Liu J, Cai M, Yan H, Fu J, Wu G, Zhao Z Int J Med Sci. 2019; 16(8):1078-1088.
PMID: 31523169 PMC: 6743274. DOI: 10.7150/ijms.33723.
Adverse drug reactions of Yunnan Baiyao capsule: a multi-center intensive monitoring study in China.
Li B, Feng S, Wu Z, Kwong J, Hu J, Wu N Ann Transl Med. 2019; 7(6):118.
PMID: 31032273 PMC: 6465448. DOI: 10.21037/atm.2019.01.62.